# B3A Migration Execution Record

- Issues: [#1057](https://github.com/mirichard/pm-tools-templates/issues/1057) (parent [#711](https://github.com/mirichard/pm-tools-templates/issues/711))
- Batch: `B3A`
- Source batch: `3`
- Asset count: `12`
- Primary domain: `Delivery`
- Rollback owner: `mirichard`
- Pre-batch SHA: `f639e285ec3970372f1fa1166b4af07d371e7fb8`
- Manifest: `meta/migration-waves/b3a.json`
- Status: **PASS — physical migration and local executed-state validation complete; integration pending**

## Scope decision

The migration inventory contained 69 pending Batch 3 / Delivery candidates at entry. The original planner selected the first twelve candidates before dependency closure. Full strongly-connected-component analysis showed that this boundary split three dependency cycles; closing every component intersecting that raw selection required 17 assets, exceeding the repository's 15-asset safety ceiling.

The migration planner and validator were corrected before any physical move. Planning now selects a deterministic source-ordered prefix while treating every same-batch/domain SCC as indivisible, and validation rejects manifests that split an SCC. Under both the normal 12-asset target and 15-asset ceiling, the first safe atomic prefix contains the same 12 assets. The next atomic component would raise the wave to 16, so it remains deferred intact.

B3A therefore contains 12 assets and splits zero SCCs.

## Assets and immutable hashes

| Legacy source | Canonical destination | Pre-move SHA-256 |
|---|---|---|
| `industry-specializations/healthcare-pharmaceutical/compliance/capa_management_template.md` | `domains/delivery/industry-specializations/healthcare-pharmaceutical/compliance/capa_management_template.md` | `c529b8195c0e169a00d64e8f397d765c873bb329bbd63340825abc62715445b4` |
| `industry-specializations/healthcare-pharmaceutical/clinical-trials/clinical_trial_protocol_template.md` | `domains/delivery/industry-specializations/healthcare-pharmaceutical/clinical-trials/clinical_trial_protocol_template.md` | `45e3419297ecf5986bd2144134578b1237bf43cfb4f3f45d049ccb417405947e` |
| `industry-specializations/healthcare-pharmaceutical/manufacturing/process_control_template.md` | `domains/delivery/industry-specializations/healthcare-pharmaceutical/manufacturing/process_control_template.md` | `5294d183cbcfa7cd148e5f8553b606cd77d02d733ae4dac72ac652527bb1371a` |
| `industry-specializations/healthcare-pharmaceutical/quality/quality_management_review_template.md` | `domains/delivery/industry-specializations/healthcare-pharmaceutical/quality/quality_management_review_template.md` | `1d0bb39160e464dc89a713e4ef865e31e8e18ab46ba1a6475a4a24f188d53181` |
| `industry-specializations/healthcare-pharmaceutical/compliance/gxp_training_plan_template.md` | `domains/delivery/industry-specializations/healthcare-pharmaceutical/compliance/gxp_training_plan_template.md` | `5ed332f0480642c30b255f26b7218f4b6dd7e71376b339015f3fcda28efe6f4a` |
| `industry-specializations/healthcare-pharmaceutical/lifecycle/pharmaceutical_qbd_template.md` | `domains/delivery/industry-specializations/healthcare-pharmaceutical/lifecycle/pharmaceutical_qbd_template.md` | `78d325c58e8f345939a6fb2efc82f82ba954f548b71befc1182f7d72930f93c0` |
| `industry-specializations/healthcare-pharmaceutical/manufacturing/batch_record_template.md` | `domains/delivery/industry-specializations/healthcare-pharmaceutical/manufacturing/batch_record_template.md` | `2028d72c48d76f6ca0e99291452e2c04f7ea855692cbd92816df4077c8b77643` |
| `industry-specializations/healthcare-pharmaceutical/manufacturing/manufacturing_batch_record_template.md` | `domains/delivery/industry-specializations/healthcare-pharmaceutical/manufacturing/manufacturing_batch_record_template.md` | `25dc484b2e9e7ac300d207246e464cb901dba925113c4e5568a53817a7f22f17` |
| `industry-specializations/healthcare-pharmaceutical/regulatory/computer_system_validation_protocol_template.md` | `domains/delivery/industry-specializations/healthcare-pharmaceutical/regulatory/computer_system_validation_protocol_template.md` | `88a04353e540a4cd6c9a6e6f62a217c6026f95107d56fd0e3cbc10bb387b3711` |
| `industry-specializations/healthcare-pharmaceutical/validation/equipment_qualification_protocol_template.md` | `domains/delivery/industry-specializations/healthcare-pharmaceutical/validation/equipment_qualification_protocol_template.md` | `fbc7a75cb552460d80e5f42b9a0694660b7230a9573dfd2766d1c721e7e22d92` |
| `industry-specializations/healthcare-pharmaceutical/validation/process_validation_master_plan_template.md` | `domains/delivery/industry-specializations/healthcare-pharmaceutical/validation/process_validation_master_plan_template.md` | `c0300e4f494b44312d3e17cc9a410dad3171cbabf61b9ee6d5e04774982ad8d5` |
| `industry-specializations/healthcare-pharmaceutical/validation/validation_master_plan_template.md` | `domains/delivery/industry-specializations/healthcare-pharmaceutical/validation/validation_master_plan_template.md` | `770b558145b2ab79d322fdacf902cee25b0fe342bedfcd584fa0712752323414` |

## Dependency-boundary evidence

The rejected raw first-twelve boundary crossed three SCCs. Completing all intersecting components required 17 assets. The corrected SCC-atomic B3A selection contains complete atomic components and defers the next four-asset component intact. Independent full-graph validation confirmed zero split SCCs across all 69 pending Delivery candidates.

## Checkpoint A — entry baseline

Authoritative baseline run: GitHub Actions run `34614165100`.

- Migration-wave tests: PASS — 15/15
- Migration-link checker tests: PASS — 5/5
- Entry manifest: PASS — 12 assets, limit 12
- Sprint strict validation: PASS — 137/137; 100% cross-reference coverage
- Curated templates: PASS — 139 templates
- Canonical paths: PASS — 0 errors; 1 inherited Stakeholder Register `path`/`canonical_path` warning
- Migration-link baseline: 63 local inline links; 2 inherited failures; 0 new failures
- CI: PASS — 1 suite, 2 tests, 100% coverage
- Entry integrity: PASS — 12/12 source hashes; 0 destination collisions

The two inherited link failures are both in `pharmaceutical_qbd_template.md`:

- `../regulatory-compliance/`
- `../clinical-research/`

## Checkpoints B/C — canonical moves and compatibility

Physical migration commit: `8024e52607c137d37f2c9b7baffe22f9ffb53585`.

GitHub Actions run `34614548665` executed the guarded atomic move.

- 12/12 canonical destination bodies match their immutable pre-move SHA-256 values.
- 12/12 legacy source paths were replaced with navigation-only pointers.
- 12/12 legacy pointers resolve to the intended canonical destination.
- Exactly 24 migration paths were staged for the physical move.
- No canonical template body was rewritten.

## Checkpoint D — canonical references and execution metadata

Reference/execution commit: `22c051de` (`refactor(b3a): canonicalize maintained references and execution metadata`).

- 12/12 inventory moves are `executed-move-with-legacy-pointer` with B3A execution metadata.
- Exactly one B3A `batch_execution_records` entry exists.
- Maintained current-reference surfaces were updated to the Delivery canonicals: current template index, template wrappers, decision-engine references, domain/cross-reference/value-flow mappings, and current catalog paths.
- Historical research, backup files, proposed snapshots, and archived evidence were intentionally not rewritten.

P5 exposed one catalog compatibility error caused by over-normalizing `alternate_paths`. Canonical `path`/`canonical_path` correctly remain on Delivery, while legacy source paths are required compatibility alternates. Commit `4ce1aa1998eced78d79f8f575d080805b9e426ac` restored the 12 legacy catalog alternate paths without changing canonical identity.

P5 also exposed one migration-created relative-link failure in the byte-preserved Pharmaceutical QbD template: `../quality-management/` resolved at the legacy hierarchy but the deferred Delivery quality-management directory did not yet exist. The canonical body was not altered. Commit `912b6469fec8f5eaed6f810dcfa5f0da49bcb26f` added a lightweight `domains/delivery/.../quality-management/README.md` compatibility-navigation shim pointing to the still-deferred maintained collection. No deferred template body was copied or prematurely migrated.

## Checkpoint E — executed-state validation

Final successful validation: GitHub Actions run `34617979386`, rerun job `103325290829`.

- Migration-wave tests: PASS — 15/15
- Migration-link checker tests: PASS — 5/5
- Executed manifest: PASS — 12 assets
- Sprint strict validation: PASS — 137/137; 100% cross-reference coverage
- Curated templates: PASS — 139 templates
- Canonical paths: PASS — 0 errors; 1 inherited Stakeholder Register warning
- Migration links: PASS — 41 files, 363 local inline links; 2 inherited failures; **0 new failures**
- CI: PASS — 1 suite, 2 tests, 100% coverage
- Destination hashes: PASS — 12/12
- Legacy pointers: PASS — 12/12
- Catalog compatibility paths: PASS — 12/12
- Inventory execution records: PASS — 12/12
- B3A batch execution records: PASS — exactly one
- Exact-body duplicate control: PASS — zero duplicate bodies for all 12 migrated canonicals
- Maintained non-catalog references: PASS — zero B3A legacy-only paths

The only remaining migration-link failures are the same two inherited entry-baseline defects (`../regulatory-compliance/` and `../clinical-research/`). B3A created zero new affected-scope link failures.

## Generator drift disposition

The metadata generator has inherited normalization drift that was already reproduced on the pre-batch main baseline. On the executed B3A state it changes only `meta/cross-references.json` and `meta/migration-inventory.json`; generated diff SHA-256 is `310d9c57a937f686a0ce401592c45e78e502dc20f91028abf2e5665f12c2b46c`. The validation explicitly proved that generator execution preserves the single B3A batch record and all 12 B3A move execution records. This non-mutating diagnostic drift was not committed as part of B3A.

## Tooling corrections established by B3A

B3A exposed and corrected two migration-tooling lifecycle defects before/while executing the wave:

1. The planner could split same-batch/domain dependency cycles because it sliced candidates before dependency analysis. Planning now selects an SCC-atomic prefix and validation rejects split-cycle manifests.
2. The migration-link checker assumed canonical destinations existed even for an entry-phase manifest. It now validates entry-phase legacy sources and executed-phase canonical destinations correctly.

Both corrections have focused regression coverage and pass the final executed-state validation.

## Checkpoint F — integration/visual validation

**Pending.** The branch-local migration is complete and validated. Integration checks must run on the final delivery head before manual merge. Visual baselines must not be updated merely to force a green result.

## Checkpoint G — post-merge verification

**Pending.** After manual integration, production `main` must reverify the 12 canonical hashes, 12 legacy pointers, catalog compatibility, required workflows, comprehensive visual regression, and rollback SHA before B3A can be treated as integrated and the next dependency-aware Delivery wave becomes authoritative.

## Technical-debt disposition

B3A is a structural migration. Canonical template bodies remained immutable. Inherited content-quality issues were not silently repaired. Existing technical-debt tracking remains under #1117 / #1058 where applicable.

## Rollback

Pre-batch rollback anchor:

`f639e285ec3970372f1fa1166b4af07d371e7fb8`

After manual integration, the wave-level rollback method is:

`git revert <B3A-merge-sha>`
